Heisz Leslie Stone
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
EW: FDA Flags High-Risk Device Recall After Patient Death. The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
PSA in REIT Comparisons and Dividend Discussions. Recent articles have compared Public Storage (PSA) to RHP as a value stock, while others explore REITs that may benefit from rising interest rates. PSA is also covered in contexts highlighting its role in dividend-focused investment strategies.
Transaction History
| INGM | ▲ Buy | Grant | 7,031 | $0 | 5/14/2026 | View on chart |
| EW | ▲ Buy | Grant | 3,251 | $0 | 5/8/2026 | View on chart |
| EW | ▼ Sell | Open Market | 2,615 | $218K | 12/12/2025 | View on chart |
| INGM | ▲ Buy | Grant | 9,615 | $0 | 6/4/2025 | View on chart |
| EW | ▲ Buy | Grant | 3,528 | $0 | 5/9/2025 | View on chart |
| EW | ▲ Buy | Option Exercise | 5,739 | $260K | 2/13/2025 | View on chart |
| EW | ▼ Sell | Open Market | 5,739 | $435K | 2/13/2025 | View on chart |
| INGM | ▲ Buy | Grant | 8,409 | $0 | 10/23/2024 | View on chart |
| EW | ▲ Buy | Grant | 3,055 | $0 | 5/8/2024 | View on chart |
| EW | ▲ Buy | Option Exercise | 7,056 | $260K | 2/8/2024 | View on chart |
| EW | ▼ Sell | Open Market | 7,056 | $610K | 2/8/2024 | View on chart |
| EW | ▼ Sell | Open Market | 3,303 | $261K | 8/10/2023 | View on chart |
| EW | ▲ Buy | Grant | 2,803 | $0 | 5/12/2023 | View on chart |
| EW | ▲ Buy | Option Exercise | 9,671 | $345K | 2/16/2023 | View on chart |
| EW | ▼ Sell | Open Market | 9,671 | $743K | 2/16/2023 | View on chart |
| EW | ▲ Buy | Grant | 2,300 | $0 | 5/4/2022 | View on chart |
| PSA | ▲ Buy | Grant | 91 | $34K | 12/31/2021 | View on chart |
| PSA | ▲ Buy | Option Exercise | 5,000 | $1.1M | 12/15/2021 | View on chart |
| PSA | ▲ Buy | Option Exercise | 5,000 | $1.1M | 12/15/2021 | View on chart |
| PSA | ▼ Sell | Open Market | 9,045 | $3.3M | 12/15/2021 | View on chart |
| PSA | ▲ Buy | Grant | 114 | $34K | 9/30/2021 | View on chart |
| PSA | ▲ Buy | Option Exercise | 5,000 | $969K | 8/20/2021 | View on chart |
| PSA | ▼ Sell | Open Market | 3,957 | $1.3M | 8/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ingram Micro (INGM) in focus after Opengear deal and analyst coverage
Recent Yahoo articles list INGM among Wall Street's favored stocks while noting some headwinds. Analysts compare its valuation to peers and point to the Opengear partnership that expands its AI infrastructure role in Europe, suggesting the stock may be undervalued. The coverage highlights potential upside as the price sits near a key support level.
Ingram Micro (INGM) in focus after Opengear deal and analyst coverage. Recent Yahoo articles list INGM among Wall Street's favored stocks while noting some headwinds. Analysts compare its valuation to peers and point to the Opengear partnership that expands its AI infrastructure role in Europe, suggesting the stock may be undervalued. The coverage highlights potential upside as the price sits near a key support level.